+1 877 705 191424 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

All Genders
ID06366048

A Model Based on Resected Normal Liver Parenchymal Volume RNLV to Predict the Risk of Post-Hepatectomy Liver Failure PHLF

Led by National Natural Science Foundation of China · Updated on 2026-04-14

1600

Participants Needed

3

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating the relationship between the volume of normal liver tissue removed during surgery, called resected normal liver parenchymal volume RNLV, and the risk of liver failure after liver surgery post-hepatetotomy liver failure, or PHLF. This observational study focuses on patients diagnosed with hepatocellular carcinoma HCC or intracholangiocarcinoma ICC who have undergone liver resection. The goal is to build and assess a personalized predictive model using RNLV to better estimate the risk of PHLF before surgery. The study collects data retrospectively from over a thousand patients treated at the investigators center. Patients are grouped based on whether they developed liver failure after surgery, defined by two sets of criteria known as the 50-50 criteria and ISGLS criteria. The research evaluates how well the RNLV-based model predicts PHLF and compares its usefulness to other methods, especially for patients with large or multiple liver tumors. Participants medical records and surgical details are reviewed to calculate RNLV and assess liver failure outcomes within 30 days after surgery. The main outcome is the predicted probability of PHLF using the newly developed model. This approach aims to improve preoperative risk assessment to support safer liver surgeries. The study is sponsored by the National Natural Science Foundation of China and runs through the end of 2026.

CONDITIONS

Brief Title

A Study on Relationship Between Resected Normal Liver Parenchymal Volume(RNLV)and Post-Hepatectomy Liver Failure (PHLF)

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Underwent selective hepatectomy surgery
  • Histologically confirmed diagnosis of hepatocellular carcinoma (HCC) or intracholangiocarcinoma (ICC)
  • Complete and accessible medical data available
Not Eligible

You will not qualify if you...

  • History of Associated Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS)
  • History of portal vein embolism (PVE)
  • History of tumor rupture
  • Emergency surgery
  • Pathological diagnosis other than HCC or ICC
  • Concomitant resection of gastrointestinal organs, spleenectomy, or other organs

Research Team

Y

Yuan-yuan Wang

G

Gang Huang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here